MAX Chat
Company Analysis BioMarin Pharmaceutical
1. Summary
Advantages
- Current debt level 8.62% is below 100% and has decreased over 5 years from 18.08%.
Disadvantages
- Price (57.28 $) is higher than fair price (21.68 $)
- Dividends (0%) are below the sector average (0.527%).
- The stock's return over the last year (-36.68%) is lower than the sector average (-1.3%).
- The company's current efficiency (ROE=8.05%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| BioMarin Pharmaceutical | Healthcare | Index | |
|---|---|---|---|
| 7 days | 1.1% | 9.1% | 1.2% |
| 90 days | -3.6% | 3.3% | 21.7% |
| 1 year | -36.7% | -1.3% | 21.8% |
BMRN vs Sector: BioMarin Pharmaceutical has significantly underperformed the "Healthcare" sector by -35.38% over the past year.
BMRN vs Market: BioMarin Pharmaceutical has significantly underperformed the market by -58.44% over the past year.
Stable price: BMRN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BMRN with weekly volatility of -0.7054% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (57.28 $) is higher than the fair price (21.68 $).
Price is higher than fair: The current price (57.28 $) is 62.2% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (30.16) is lower than that of the sector as a whole (64.15).
P/E vs Market: The company's P/E (30.16) is lower than that of the market as a whole (90.03).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.28) is lower than that of the sector as a whole (18.96).
P/BV vs Market: The company's P/BV (2.28) is lower than that of the market as a whole (9.39).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.51) is lower than that of the sector as a whole (32.77).
P/S vs Market: The company's P/S indicator (4.51) is lower than that of the market as a whole (10.12).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (19.27) is lower than that of the sector as a whole (274.79).
EV/Ebitda vs Market: The company's EV/Ebitda (19.27) is lower than that of the market as a whole (50.91).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -10.06% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-10.06%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (8.05%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (8.05%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (6.17%) is higher than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (6.17%) is lower than that of the market as a whole (6.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0.79%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0.79%) is lower than that of the market as a whole (11.08%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
